Propanc Biopharma, Inc. PPCB
1.74 USD -0.06 (-3.42%)
Nov 3, 2026, 3:11 PM EST
1.69 52-week range 315.00
- YTD
- -98.70%
- 1 year
- -99.38%
Altman Z-Score
-19.78 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-3 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
P/E -0.1×
P/S 0.0×
P/B 0.2×
P/FCF -0.3×
EV/EBITDA -0.0×
EV/Sales 0.0×
FCF Yield -337.1%
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -200.6%
ROIC -192.4%
ROA -147.6%
Revenue 0.0%
Operating Income 68.3%
EPS (diluted) 95.3%
Free Cash Flow -1302.5%
Current Ratio 2.5×
Quick Ratio 2.5×
Debt / Equity 0.0×
Net Debt / EBITDA 0.0×
Interest Coverage -42.2×
Dividend Yield 55.3%
Payout Ratio -4.9%
Annual · latest fiscal year ends 2026-06-30